Chronic Glutamate Toxicity in Neurodegenerative Diseases-What is the Evidence?
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing mechanisms and preclinical animal studies with no human clinical trial data.
PubMed 26733784 · doi:10.3389/fnins.2015.00469
What was done
This narrative review synthesized literature on the biological pathways driving glutamatergic system overactivation and chronic glutamate toxicity across neurodegenerative conditions, including amyotrophic lateral sclerosis, Alzheimer's disease, and Huntington's disease, focusing on evidence from animal models.
What was found
The abstract reports no quantitative values or statistical metrics. It describes the physiological concentration gradient of glutamate (millimolar intracellular vs. micromolar extracellular maintained by amino acid transporters) and summarizes experimental evidence of ionotropic receptor-mediated excitotoxicity in preclinical disease models.
Why it matters
It outlines the mechanistic framework supporting the development of neuroprotective drugs that block glutamate receptors or enhance extracellular clearance in chronic neurodegeneration.
Limits
The paper is a narrative review without systematic search protocols. It relies primarily on in vitro and animal models rather than direct human clinical trial data, limiting translational certainty.
Cited by
- supports Glutamate is present in the brain in millimolar concentrations, whereas monoamine neurotransmitters are in micromolar concentrations.